Skip to content
10-K

Annual Report

Aprea Therapeutics, Inc. APRE

0001104659-26-028068

← back to feed
Filed
Mar 16, 2026 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2025 · Mar 16, 2026 11.45M sh
Shares Diluted FY 2025 · Dec 31, 2025 6.54M sh
Shares Diluted FY 2025 · Dec 31, 2024 5.51M sh
Operating Cash Flow FY 2025 · Dec 31, 2025 −$12.89M
Operating Cash Flow FY 2025 · Dec 31, 2024 −$13.56M
Cash And Equivalents FY 2025 · Dec 31, 2025 $14.6M
Cash And Equivalents FY 2025 · Dec 31, 2024 $22.85M
Stockholders Equity FY 2025 · Dec 31, 2025 $12.44M
Stockholders Equity FY 2025 · Dec 31, 2024 $19.31M
Stockholders Equity FY 2025 · Dec 31, 2023 $16.95M
Current Liabilities FY 2025 · Dec 31, 2025 $2.76M
Current Liabilities FY 2025 · Dec 31, 2024 $3.36M
Current Assets FY 2025 · Dec 31, 2025 $15.56M
Current Assets FY 2025 · Dec 31, 2024 $23.58M
Total Assets FY 2025 · Dec 31, 2025 $15.93M
Total Assets FY 2025 · Dec 31, 2024 $23.98M
Eps Diluted FY 2025 · Dec 31, 2025 −$1.93
Eps Diluted restated FY 2025 · Dec 31, 2024 −$2.35
Eps Basic FY 2025 · Dec 31, 2025 −$1.93
Eps Basic FY 2025 · Dec 31, 2024 −$2.35
Sga Expense FY 2025 · Dec 31, 2025 $6.48M
Sga Expense FY 2025 · Dec 31, 2024 $6.46M
Net Income FY 2025 · Dec 31, 2025 −$12.6M
Net Income FY 2025 · Dec 31, 2024 −$12.96M
Operating Income FY 2025 · Dec 31, 2025 −$13.23M
Operating Income FY 2025 · Dec 31, 2024 −$14.32M
Capex FY 2025 · Dec 31, 2024 $15.48K